FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on Labeling
Authors:
- 1 September 1999
- journal article
- case report
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 39 (9) , 899-910
Abstract
Recent advances in in vitro metabolism methods have led to an improved ability to predict clinically relevant metabolic drug‐drug interactions. To address the relationships of in vitro metabolism data and in vivo metabolism outcomes, the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research, Food and Drug Administration, evaluated a number of recently approved new drug applications. The goal of these evaluations was to determine the contribution of in vitro metabolism data in (1) predicting in vivo drug‐drug interactions, (2) determining the need to conduct an in vivo drug‐drug interaction study, and (3) incorporating findings into drug product labeling. Ten cases are presented in this article. They fall into two major groups: (1) in vitro data were predictive of in vivo results, and (2) in vitro data were not predictive of in vivo results. Discussion of these cases highlights factors limiting predictability of in vivo metabolic interactions from in vitro metabolism data. The integration of these findings into drug product labeling is also discussed.Keywords
This publication has 39 references indexed in Scilit:
- Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis IssuesThe Journal of Clinical Pharmacology, 1999
- QUANTITATIVE PREDICTION OF IN VIVO DRUG CLEARANCE AND DRUG INTERACTIONS FROM IN VITRO DATA ON METABOLISM, TOGETHER WITH BINDING AND TRANSPORTAnnual Review of Pharmacology and Toxicology, 1998
- In Vitro Approaches to Predicting Drug Interactions In VivoBiochemical Pharmacology, 1998
- Prediction of In Vivo Drug Interaction from In Vitro Systems Exemplified by Interaction Between Verapamil and Cimetidine Using Human Liver Microsomes and Primary HepatocytesThe Journal of Clinical Pharmacology, 1997
- Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive MetabolizersJournal of Clinical Psychopharmacology, 1997
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- A fluvoxamine-caffeine interaction studyPharmacogenetics, 1996
- Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and FluvoxamineJournal of Clinical Psychopharmacology, 1995
- Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.British Journal of Clinical Pharmacology, 1995
- Utility of in vitro drug metabolism data in predicting in vivo metabolic clearanceBiochemical Pharmacology, 1994